| Rha, Sun Young |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
NCT05512182: Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression |
|
|
| Withdrawn | 2 | 50 | RoW | Chemotherapy | Yonsei University | Recurrent/Advanced Gastric Cancer | 10/23 | 10/23 | | |
NCT05270889: Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial |
|
|
| Not yet recruiting | 2 | 50 | RoW | Tislelizumab+Zanidatamab | Yonsei University | HER2-positive Gastric Cancer | 06/24 | 06/24 | | |
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 74 | Canada, US, RoW | ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine | Jazz Pharmaceuticals | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | 07/25 | 07/25 | | |
HER-RAM, NCT04888663: Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer ( Study) |
|
|
| Active, not recruiting | 1/2 | 50 | RoW | Trastuzumab + Ramucirumab + Paclitaxel | Yonsei University | Recurrent/Metastatic Gastric Cancer | 09/21 | 09/21 | | |
NCT05400915: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients |
|
|
| Completed | 1/2 | 27 | RoW | Variltinib, Paclitaxel | Yonsei University | Gastric Cancer | 12/21 | 06/22 | | |
NCT05529667: Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy. |
|
|
| Completed | 1/2 | 15 | RoW | INCB054828, Paclitaxel | Yonsei University | Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel | 08/23 | 08/23 | | |
NCT04592211: Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer |
|
|
| Recruiting | 1/2 | 71 | RoW | olaparib+pembrolizumab+paclitaxel | Yonsei University | Gastric Cancer Stage IV | 12/24 | 05/25 | | |
YH32367-101, NCT05523947: Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor |
|
|
| Recruiting | 1/2 | 137 | RoW | YH32367 | Yuhan Corporation | HER2-Positive Solid Tumor | 10/26 | 12/26 | | |
NCT04835896: Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer |
|
|
| Completed | 1/2 | 49 | RoW | M7824+paclitaxel | Yonsei University | Recurrent/Metastatic Gastric Cancer | 10/23 | 10/23 | | |
NCT05894824: T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
|
|
| Recruiting | 1/2 | 58 | RoW | T-Dxd(Trastuzmab deruxtecan), Ramucirumab, Enhertu, Cyramza | Yonsei University | Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer | 05/25 | 01/26 | | |
NCT05508737: Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer |
|
|
| Active, not recruiting | 1/2 | 75 | RoW | Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®), Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®) | Yonsei University | Gastric and Gastroesophageal Junction Adenocarcinoma | 05/25 | 12/25 | | |
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers |
|
|
| Completed | 1 | 112 | Canada, US, RoW | ZW49 | Zymeworks BC Inc. | HER2-expressing Cancers | 09/24 | 10/24 | | |
| Recruiting | 1 | 260 | US, RoW | CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi® | Coherus Biosciences, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 12/25 | 08/26 | | |
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer |
|
|
| Active, not recruiting | 1 | 70 | US, RoW | TORL-2-307-MAB | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/25 | | |
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer |
|
|
| Recruiting | 1 | 70 | US, RoW | TORL-2-307-ADC | TORL Biotherapeutics, LLC, Translational Research in Oncology | Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 01/26 | | |
NCT02951091: Biomarker-Integrated Umbrella, Advanced Gastric Cancer |
|
|
| Completed | N/A | 400 | RoW | biomarker screening | Yonsei University | Gastric Cancer | 12/21 | 03/24 | | |
| Recruiting | N/A | 80 | RoW | | Yonsei University | Advanced Gastric Cancer | 12/26 | 12/26 | | |
| Jung, minkyu |
NCT05882292: c-MET Inhibitor in Advanced Solid Tumors With c-MET Gene Aberration |
|
|
| Recruiting | 2 | 20 | RoW | ABN401, c-MET inhibitor | Yonsei University | Neoplasms | 12/25 | 12/25 | | |
NCT05436990: Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor |
|
|
| Not yet recruiting | 2 | 30 | RoW | Pembrolizumab, Vactosertib | Yonsei University | Acral Melanoma, Mucosal Melanoma | 07/25 | 12/25 | | |
NCT04777994: A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors |
|
|
| Recruiting | 1 | 248 | Europe, Japan, US, RoW | ABBV-CLS-484, Programmed Cell Death-1 (PD-1) Inhibitor, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) | AbbVie, Calico Life Sciences LLC | Advanced Solid Tumor Cancer | 08/25 | 10/26 | | |
| Recruiting | 1 | 120 | Japan, US, RoW | EO-3021 | Elevation Oncology | Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms | 09/28 | 12/28 | | |
NCT05584592: A Randomized Controlled Trial of Integrated Early Palliative Care for Advanced Gastric Cancer Patients |
|
|
| Recruiting | N/A | 170 | RoW | Intergrate early palliatuve care + Conventional chemotherapy, Conventional chemotherapy | Yonsei University | Advanced Gastric Cancer | 11/22 | 02/23 | | |
NCT05573776: A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy |
|
|
| Completed | N/A | 80 | RoW | Exercise Therapy, High Protein supplement | Yonsei University | Gastric Cancer, Pancreatic Cancer | 12/22 | 01/23 | | |
NCT06767436: A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer |
|
|
| Recruiting | N/A | 300 | RoW | | Yonsei University | Advanced Gastric Cancer | 11/25 | 11/25 | | |
